海正生材: 浙江海正生物材料股份有限公司股东减持股份计划公告

Core Viewpoint - The major shareholder, Sinopec Capital, plans to reduce its stake in Zhejiang Haizheng Biomaterials Co., Ltd. due to funding needs for business development, intending to sell up to 3,525,600 shares, which represents no more than 1.74% of the total share capital [1][2]. Group 1: Shareholder Information - Sinopec Capital holds 13,659,494 shares, accounting for 6.74% of the total share capital of the company [1][2]. - The shares held by Sinopec Capital were acquired before the company's initial public offering (IPO) and became tradable on February 19, 2024 [1][2]. Group 2: Reduction Plan Details - The reduction plan allows Sinopec Capital to sell up to 3,525,600 shares within three months starting from fifteen trading days after the announcement [1][2]. - The selling price will be determined based on the market price at the time of the sale [1][2]. - If there are any changes in the company's total share capital due to stock dividends, capital increases, or other corporate actions, the number of shares to be reduced will be adjusted accordingly [1][2]. Group 3: Compliance and Commitments - Sinopec Capital has committed to not transferring or managing the shares held prior to the IPO for a period of twelve months from the listing date or three years from the date of share acquisition, whichever is later [3][4]. - The shareholder will comply with relevant laws and regulations during the reduction process and will ensure timely disclosure of information [4][5].